Literature DB >> 15503653

Gadofosveset (EPIX/Schering).

Aamer Farooki1, Vamsidhar Narra, Jeffrey Brown.   

Abstract

EPIX Medical and Schering are developing gadofosveset, an albumin-binding gadolinium-based intravascular magnetic resonance imaging contrast agent, for the potential imaging of blood vessels and blood flow, particularly in patients with peripheral vascular disease (PVD). By February 2004, US approval of the agent was anticipated in October 2004, and in June 2004, Schering filed an MAA in the EU for PVD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15503653

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  6 in total

1.  Intravascular contrast agent T1 shortening: fast T1 relaxometry in a carotid volunteer study.

Authors:  Michael Bock; Jessica Schulz; Stefan Ueltzhoeffer; Frederik Giesel; Matthias Voth; Marco Essig
Journal:  MAGMA       Date:  2008-08-29       Impact factor: 2.310

2.  Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation.

Authors:  M M Stollenwerk; I Pashkunova-Martic; C Kremser; H Talasz; G C Thurner; A A Abdelmoez; E A Wallnöfer; A Helbok; E Neuhauser; N Klammsteiner; L Klimaschewski; E von Guggenberg; E Fröhlich; B Keppler; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2010-02-20       Impact factor: 4.304

Review 3.  Magnetic Resonance Imaging of the Liver (Including Biliary Contrast Agents) Part 1: Technical Considerations and Contrast Materials.

Authors:  A Agostini; M F Kircher; R Do; A Borgheresi; S Monti; A Giovagnoni; L Mannelli
Journal:  Semin Roentgenol       Date:  2016-05-30       Impact factor: 0.800

4.  High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.

Authors:  Josep Puig; Gerard Blasco; Josep Daunis-I-Estadella; Angel Alberich-Bayarri; Marco Essig; Rajan Jain; Sebastián Remollo; David Hernández; Montserrat Puigdemont; Javier Sánchez-González; Gloria Mateu; Max Wintermark; Salvador Pedraza
Journal:  Neuroradiology       Date:  2015-10-05       Impact factor: 2.804

5.  Human brain tumor imaging with a protein-binding MR contrast agent: initial experience.

Authors:  Marco Essig; Martin Rohrer; Frederik Giesel; Jochen Tüttenberg; Marc-André Weber; Hendrik Michaely; Lars Gerigk; Matthias Voth
Journal:  Eur Radiol       Date:  2009-08-12       Impact factor: 5.315

6.  Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma.

Authors:  Josep Puig; Gerard Blasco; Marco Essig; Josep Daunis-I-Estadella; Gemma Laguillo; Ana María Quiles; Sebastián Remollo; Karsten Bergmann; Carme Joly; Lluis Bernado; Javier Sánchez-González; Salvador Pedraza
Journal:  Eur Radiol       Date:  2012-10-21       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.